Award Number: W81XWH-11-1-0043

TITLE: Regulation of Mammary Stem Cell Quiescence via Post-Translational Modification of DeltaNp63alpha

PRINCIPAL INVESTIGATOR:
Andrew J. DeCastro

CONTRACTING ORGANIZATION:
Dartmouth College
Hanover, NH 03755

REPORT DATE: February 2014

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be
construed as an official Department of the Army position, policy or decision unless so designated by
other documentation.
This document is the annual summary report for the training grant awarded to Andrew DeCastro entitled Regulation of Mammary Stem Cell Quiescence via Post-Translational Modification of ΔNP63α. Here, we report our findings under Task 3, as we have already completed our work on Tasks 1 and 2 in past years. Task 3 aims to determine the contribution of ΔNP63α and ΔNP63α-phosphorylation to therapeutic resistance in breast cancer stem cells. Based on previous work, in which we show that TGF-β mediates ALK5 dependent phosphorylation of ΔNP63α, we also observed noticeable changes in cell phenotype indicative of EMT, a process utilized by cancer cells to mediate invasiveness, metastasis, chemoresistance and recurrence. As a result, we sought to determine the contribution of ΔNP63α and its phosphorylation to the process of EMT and demonstrated that ΔNP63α not only opposes TGF-β induced EMT, but was sufficient to reverse a post-EMT breast cancer cell line back towards a more epithelial phenotype (MET). The data presented here identifies a role for ΔNP63α as a potent opposed to TGF-β mediated EMT.
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>6</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>6</td>
</tr>
<tr>
<td>Conclusion</td>
<td>7</td>
</tr>
<tr>
<td>References</td>
<td>7</td>
</tr>
<tr>
<td>Appendices</td>
<td>7</td>
</tr>
</tbody>
</table>
Introduction
The training grant entitled, “Regulation of Mammary Stem Cell Quiescence via Post-Translational Modification of ΔNp63α”, seeks to identify the kinase(s) responsible for the phosphorylation of ΔNp63α at serines 66 and 68 and to further characterize and understand the biological consequences of such phosphorylation. The purpose of the work funded by the above titled training grant aims to identify the particular function of serine 66/68 phosphorylation specifically on mammary stem cell regulation and phenotype and whether it may contribute to breast cancer progression, phenotype and/or recurrence. Completion of this work will further our understanding of the regulation and roles of ΔNp63α in the mammary gland and its contribution to breast tumorigenesis. Additionally, identification of the kinases responsible for such phosphorylation and its influence over ΔNp63α activity may make them favorable candidates for therapeutic targets.

Body

Task 1: Determine the effects of wild-type, phosphor-ablative and phosphor-mimetic alleles of ΔNp63α phosphorylation on stem cell behavior in vitro.

For this particular aim, we sought to explore the role and regulation of ΔNp63α in adult mammary stem cells resultant of phosphorylation at serines 66 and 68. In previous annual summary reports we have characterized such functions and consequently completed our work for this task. Briefly, we identified a relationship between phosphor-p63 expression and a quiescent-like state as observed via reduced rates of proliferation and accumulation of cells in G0/G1 of the cell cycle. Following a screening assay to identify the kinase(s) responsible, our top candidate was TGFβR1, also known as ALK5 (Task 2), for which we began to characterize the function of this kinase on phosphorylation of ΔNp63α and its downstream activity, which we characterize and complete in task 2 of the training grant (1)(Appendix 1- annual summary report:2012 – containing publication).

Task 2: Identify putative ΔNp63α-kinases and determine their role in mitotic activation of ΔNp63α-positive cells.

In the previous annual summary report we had completed task 2, resulting in a publication, all of which can be seen in appendix 1 (Annual summary report – 2012 with publication). Briefly, we determined that upon stimulation with TGF-β, the intracellular domain of the ALK5 kinase is cleaved and translocates into the nucleus where it is able to phosphorylate ΔNp63α. ALK5 mediated phosphorylation of ΔNp63α resulted in an accumulation of cells in G0/G1 phase of the cell cycle, indicating an anti-proliferative phenotype (Appendix 1: Figure 5B). Taken together, we concluded that phosphorylation of ΔNp63α by ALK5 was a destabilizing, anti-proliferative and anti-clonogenic event (Appendix 1).

Task 3: Determine the contribution of ΔNp63α and ΔNp63α-phosphorylation to therapeutic resistance in breast cancer stem cells.

During our experiments to further characterize the function of ALK5-mediated phosphorylation of ΔNp63α (Tasks 1 & 2), we observed significant morphological changes in cells treated in the presence of TGF-β (500 pM), the ligand of ALK5 (Figure 1A). These changes were indicative of an epithelial-to-mesenchymal transition (EMT). Moreover, this observed EMT in response to TGF-β was inhibited via co-treatment with the ALK5 small molecular inhibitor A83-01 (2 μM) as indicated via morphological phenotype and immunoflorescent staining against E-cadherin, a marker of epithelial cells (Figure 1A). To further characterize this observed morphological change in response to TGF-β as EMT we performed a

![Figure 1: TGF-β stimulates EMT in MCF10A cells](image)
A scratch assay, a measure of the invasive properties of EMT cells (Figure 1B). Cells were plated at near confluent density and were subsequently treated with either no treatment control, TGF-β (500 pM) or TGF-β (500 pM) and A83-01 (2 μM). A scratch was then made down the middle of the plate, and re-colonization of the scratch was measured 48 hours after the scratch to measure the invasive properties. As indicated via the images (Figure 1B), TGF-β greatly increased the invasive properties of MCF10A cells, and this was significantly diminished via co-treatment with A83-01. Likewise, EMT was further validated in TGF-β treated cells via qRT-PCR analysis revealing a significant relative induction of EMT associated genes Pai1, Snai1 and Slug (Figure 1C). These results are significant as EMT is a key developmental program that can be reactivated upon tumorigenesis and has been linked to tumor invasion, metastasis, chemoresistance and recurrence. Additionally, cancer cells that have undergone EMT acquire a cancer stem cell phenotype (2-4). This, taken together with our results demonstrating TGF-β mediated ALK5 phosphorylation of ΔNp63α raised the question of whether ΔNp63α may oppose EMT.

To answer this, we first analyzed the morphology of cells in response to TGF-β treatment in the presence or absence of constitutive ΔNp63α expression (Figure 2A). MCF10A cells were seeded onto a place at sub-confluence and then treated with either TGF-β (50 pM), A83-01 (2 μM), an adenovirus to overexpress ΔNp63α or ΔNp63α overexpression and TGF-β. Three days post treatments, compared to vehicle, which are highly epithelial in structure; TGF-β treated cells had undergone an EMT, as indicated via less organized and less tight junctions and less rounded all features of mesenchymal cells. Conversely, ectopic expression of ΔNp63α garnered cells with a more rounded epithelial phenotype, which remained relatively unperturbed via the introduction of TGF-β (Figure 2A), suggesting that ΔNp63α opposes TGF-β induced EMT.

Likewise, when we analyzed the expression of Slug and Vimentin, two proteins associated with EMT via western blot, we saw that ΔNp63α was able to prevent the observed induction of these proteins in response to TGF-β (Figure 2B), further validating ΔNp63α’s role in opposing EMT. Finally, we analyzed the mRNA expression of multiple genes implicated in EMT (Vimentin, ZEB1 and N-Cadherin) in response to siRNA mediated knockdown of endogenous ΔNp63α in the presence or absence of the EMT inducing molecule TGF-β (Figure 2C). To do this we first transfected cells with either scramble or siRNA directed against ΔNp63α (20nM). Twenty four hours post transfection, cells were then treated with TGF-β (50pM) and subsequently collected for qRT-PCR analysis 24 hours later. In response to siRNA-knockdown of ΔNp63α, compared to scramble control, there was an induction of mRNA of the pro-EMT gene Vimentin, however, there was little to no change in the expression of the other two pro-EMT genes analyzed. As expected, in response to TGF-β alone, there was a large induction of all three pro-EMT genes mRNA expression. Interestingly, this was further increased in response to siRNA mediated ablation of ΔNp63α, further suggesting that ΔNp63α opposes TGF-β mediated EMT (Figure 2C).
Finally, we wanted to determine if ΔNp63α was sufficient to induce an MET in a cell line that is phenotypically in an EMT state. For this, the MDA-MB-231 breast cancer cell line was used, which are post-EMT and display highly aggressive and invasive characteristics that are hallmarks of EMT. Additionally, MDA-MB-231 cells do not express detectible levels of ΔNp63α. Upon adenoviral overexpression of ΔNp63α, MDA-MB-231 cells appeared more epithelial in structure and had highly organized tight junctions compared to adenoviral control (Figure 3A). Likewise, when we performed scratch assays, similar to that described above, we observed a significant reduction in MDA-MB-231 cells to migrate into the cleared area in the presence of ΔNp63α, further illustrating ΔNp63α’s potent anti-EMT, pro-MET effects (Figure 3B). Additionally, when we treated MDA-MB-231 cells with either ΔNp63α or the ALK5 inhibitor A83-01, there was an observed reduction in the mRNA expression of the three EMT markers Vimentin, SLUG and ZEB1 (Figure 3C). Both ΔNp63α and A83-01 treatment phenocopy each other, which is supported by our previous finding showing that TGF-β mediated ALK5 phosphorylation of ΔNp63α is a destabilizing event of ΔNp63α, therefore enabling TGF-β to promote EMT. However, in the presence of this inhibitor (A83-01), phosphorylation of ΔNp63α is prevented, thereby enabling ΔNp63α to oppose EMT and promote MET. Finally, to further validate ΔNp63α’s role in mediating MET, western blot analysis for cytokeratin’s indicative of an epithelial phenotype (cytokeratin’s 14 & 17) were performed in MDA-MB-231 cells treated with vehicle and adenoviral control, or an adenovirus expressing ΔNp63α, or A83-01 (Figure 3D). Results show that ΔNp63α is sufficient to induce expression of cytokeratin’s 14 and 17, which is consistent with the induction of an epithelial phenotype Figure 3D).

**Key Research Accomplishments**
- Determined that TGF-β induces EMT in the breast cell line MCF10A.
- Determined that ectopic ΔNp63α was able to block TGF-β mediated induction of EMT in MCF10A cells.
- Determined that ΔNp63α is sufficient to convert a post-EMT breast cancer cell line (MDA-MB-231) to an epithelial phenotype via MET.

**Reportable Outcomes**
- There are no reportable outcomes at this time. However, we intend to submit a manuscript, of which the above reported data is part of within the near future.
Conclusions

To date, we have shown that ΔNp63α is able to oppose TGF-β mediated EMT of normal and breast cancer cells. Additionally we show that ΔNp63α is able to revert post-EMT cells back towards and epithelial phenotype. Moreover, based on the observations that ALK5 inhibition via A83-01 was able to phenocopy the effects of ΔNp63α overexpression with result to MET, it suggests that TGF-β may be mediating its pro-EMT effects through activation and subsequent phosphorylation of ΔNp63α by ALK5, which we have previously shown is a destabilizing event. Collectively, the data suggests that ΔNp63α is present to oppose EMT, which is a process utilized by breast cancer to promote invasiveness, metastasis and overall poor prognosis in cancer patients. This data also brings to light the possible utility of using an ALK5-inhibitor in the clinic to prevent or reverse the process of EMT and its subsequent regulation over tumor phenotype.

References


Appendices

Appendix 1:
W81XWH-11-1-0043 Annual Summary Report 2012 containing the following publication:
**14. ABSTRACT**

This document is the Annual Summary Report on the training grant awarded to Andrew DeCastro entitled *Regulation of Mammary Stem Cell Quiescence via Post-translational Modification of ∆NP63α*. Here, we report our findings of the effects of TGFβ (previously validated as a kinase in our kinome screen) mediated phosphorylation of ∆NP63α on stem cell behavior and mitotic activity. Task 1 aims to determine the effects of wild-type, phospho-ablative and phospho-mimetic alleles of ∆NP63α phosphorylation on stem cell behavior in vitro. Thus far, we demonstrate that stem cell enriched populations, as indicated by ALDH1 activity, contain higher concentrations of ∆NP63α mRNA. In addition, we demonstrate that the anti-clonogenic effects of TGFβ are mediated through phosphorylation of ∆NP63α, which is rescued via ectopic expression of the phospho-ablative mutant ∆NP63α-AA. Task 2 aims to identify putative ∆NP63α-kinases and determine their role in mitotic activation. Here we further characterize TGFβ-mediated phosphorylation of ∆NP63α. We demonstrate that TGFβ phosphorylation of ∆NP63α is a destabilizing event, and dependent on the proteasomal degradation pathway. We also report a non-canonical pathway in which ALK5 (TGFβR1) is cleaved from the membrane and translocates to the nucleus, where it phosphorylates ∆NP63α. Due to our focus on Task 1 and 2, we have not yet begun our investigation of Aim 3.

**15. SUBJECT TERMS**

Breast Cancer, stem cells, quiescence, phosphorylation, ∆NP63α, TGF-β
Award Number:
W81XWH-11-1-0043

TITLE:
Regulation of Mammary Stem Cell Quiescence via Post-translational Modifications of ΔNP63α

PRINCIPAL INVESTIGATOR:
Andrew J. DeCastro

CONTRACTING ORGANIZATION:
Dartmouth College
Hanover, NH 03755

REPORT DATE:
December 14th, 2012

TYPE OF REPORT:
Annual Summary Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be
conscrued as an official Department of the Army position, policy or decision unless so designated by
other documentation.
# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>4</td>
</tr>
<tr>
<td>Body</td>
<td>4</td>
</tr>
<tr>
<td>Key Research Accomplishments</td>
<td>5</td>
</tr>
<tr>
<td>Reportable Outcomes</td>
<td>5</td>
</tr>
<tr>
<td>Conclusion</td>
<td>6</td>
</tr>
<tr>
<td>References</td>
<td>6</td>
</tr>
<tr>
<td>Appendices</td>
<td>7</td>
</tr>
</tbody>
</table>
Introduction
The training grant entitled, “Regulation of Mammary Stem Cell Quiescence via Post-translational Modification of ∆NP63α”, aims to identify the kinase(s) responsible for phosphorylation of ∆NP63α at serines 66 and 68 and to characterize the function of this phosphorylation. More specifically, the purpose of this research is to characterize the contribution of this phosphorylation on stem cell and mitotic activity, and whether it plays a role in breast cancer recurrence. Completion of this research will further add to our understanding of the role and regulation ∆NP63α in mammary and cancer stem cells, and identify kinases as therapeutic targets to minimize or reduce breast cancer recurrence, a significant contributor of breast cancer mortality.

Body

Task 1: Determine the effects of wild-type, phospho-ablative and phospho-mimetic alleles of ∆NP63α phosphorylation on stem cell behavior in vitro.

∆NP63α has been shown to play a critical role in maintaining replicative capacity of adult epithelial stem cells, and because many mechanisms of normal stem cell function are utilized in cancer stem cells to garner therapeutic resistance and recurrence(1-3), we sought to explore the role and regulation of ∆NP63α in adult mammary stem cells. In the past annual summary report, we identified a relationship between phospho-p63 expression and a quiescent state, which is a feature often utilized by mammary stem cells to maintain replicative potential. Additionally, we also performed a kinase screening assay to determine the kinase(s) responsible for this phosphorylation and identified TGFβR1 (ALK5) as a kinase. In this report, we characterize the function of TGFβ- mediated phosphorylation of ∆NP63α on stem cell behavior. To do this, we treated immortalized mammary epithelial cells (IMECs) with vehicle control, TGFβ or TGFβ in the presence of A83-01 (small molecule inhibitor of ALK5) up to 72 hours and measured cell number. Results indicate that TGFβ significantly reduced cell growth and was rescued via inhibition of TGFβ by A83-01 (Appendix 1, figure 5A). This coincided with an increase of cells in G0/G1 compared to vehicle control, and was rescued with addition of A83-01 (Appendix 1: Figure 5B). Together, these results demonstrate that TGFβ has an anti-proliferative effect in IMECs, which is a common feature of stem cells. When IMECs were FACS sorted based on ALDH activity (a marker of stem cells) and analyzed for ∆NP63α mRNA expression, ALDH-high fractions, which are enriched for stem cells, had significantly higher levels of ∆NP63α (Appendix 1: Figure 5C). ALDH activity was then assessed in cells treated with vehicle, TGFβ or A83-01. TGFβ treated cells had reduced ALDH activity compared to controls which was rescued via A83-01 treatment (Appendix 1: Figure 5D). Collectively, these results identify ∆NP63α to be highly expressed in stem cell fractions, which are reduced via addition of TGFβ, which activates a kinase we validated that phosphorylates ∆NP63α. In addition, we show that TGFβ mediated phosphorylation of ∆NP63α is a destabilizing event (Appendix: Figure 6). Taken together, our results suggest that the TGFβ-mediated reduction of ALDH activity, a marker of stem cells, is mediated through phosphorylation and subsequent reduction of ∆NP63α protein, a known regulator of stem cell maintenance. Furthermore, we demonstrate that the anti-clonogenic activity of TGFβ is mediated, in part, through phosphorylation of ∆NP63α, which was rescued via ectopic expression of the phospho-ablative mutant ∆NP63α-AA (Appendix1: Figure 7). Thus far, this series of experiments represent our findings for this task for the given period of the report, furthermore, they are part of an original research paper published in the November 2012, volume 7, issue 11 of PLoS1 Journal (Appendix 1).

Task 2: Identify putative ∆NP63α-kinases and determine their role in mitotic activation of ∆NP63α-positive cells.

In the previous annual summary report, we identified putative kinases that phosphorylate ∆NP63α including TGFβR1 (ALK5). Due to its significance in cell and cancer biology (4, 5) we validated and confirmed TGFβR1 as a kinase of ∆NP63α using three different siRNAs against the receptor. Since then, we have characterized the mechanisms and the functions of TGFβR1-mediated phosphorylation of ∆NP63α which have been published in an original paper in PLoS1 Journal (Appendix 1). To determine if TGFβR1 (ALK5) directly phosphorylates ∆NP63α, we performed an in vitro kinase assay in which affinity purified ALK5 and ∆NP63α were incubated together at varying concentrations. The protocol for this assay is detailed in the materials and methods section of the publication (Appendix 1). Western blot analysis for phosphorylation on stem cell and mitotic activity, and whether it plays a role in breast cancer recurrence. Completion of this research will further add to our understanding of the role and regulation ∆NP63α in mammary and cancer stem cells, and identify kinases as therapeutic targets to minimize or reduce breast cancer recurrence, a significant contributor of breast cancer mortality.
if phosphorylation of ΔNP63α requires TGFβR2, which does bind TGFβ. Western blot analysis of cells co-transfected with/without an siRNA against TGFβR2 and with/without ΔNP63α revealed that this phosphorylation event requires TGFβR2 and that phosphorylation of ΔNP63α is facilitated via the association of ALK5 and TGFβR2, which is mediated through TGFβ ligand stimulation (Appendix1: Figure 2C and 2D respectively).

Next, we examined the mechanism by which a cell surface kinase (ALK5) can phosphorylate ΔNP63α, a nuclear protein. Western blot analysis of IMECs treated with siRNA against ALK5 revealed a 34kDa fragment that coincided with the intracellular region of ALK5 (Appendix1: Figure 6A). Previous studies have made evident that the intracellular region of ALK5 is sensitive to proteolytic cleavage where it then accumulates in the nucleus (6). To determine if this observed intracellular fragment of ALK5 localizes to the nucleus, we isolated nuclear and cytoplasmic lysates from IMECs, which were then analyzed via western blot to detect the localization of cleaved ALK5. We observed accumulation of the cleaved fragment in the nucleus (Appendix1: Figure 6C). Additionally, when we transfected an ALK5-GFP fusion expression vector into H1299 cells and subsequently treated with vehicle or TGFβ, we were able to show that the fusion protein localizes to the nucleus (Appendix1: Figure 6D). This nuclear accumulation was also found to occur with endogenous ALK5 in response to TGFβ stimulation (Appendix1: Figure 6E). Taken together, we demonstrate that ΔNP63α is phosphorylated in response to TGFβ through cleavage of the intracellular ALK5 domain, which subsequently translocates into the nucleus.

Thus far, we have further characterized the mechanism(s) of ALK5 mediated phosphorylation of ΔNP63α. We determined that this phosphorylation is direct, is in response to TGFβ ligand stimulation and requires TGFβR2. Furthermore, we demonstrate that the intracellular domain of ALK5 translocates into the nucleus to phosphorylate ΔNP63α. We are currently in the process of further characterizing the biological significance of the observed TGFβ mediated phosphorylation of ΔNP63α with respect to mitotic and stem cell activity.

Task 3: Determine the contribution of ΔNP63α and ΔNP63a-phosphorylation to therapeutic resistance in breast cancer stem cells.

Due to our heavy focus on Task 1 and 2, we have only recently begun work focusing on Task 3. Previous publications have made evident that ΔNP63α is phosphorylated upon UV-irradiation (7). We sought to determine if this phosphorylation is mediated through the TGFβ-ALK5 signaling pathway. To do this, we plated IMECs and treated them with mock or UV-irradiation followed by vehicle or A83-01 (small molecular inhibitor of ALK5). Western blot analysis revealed inhibition of UV-induced phosphorylation of ΔNP63α when ALK5 was inhibited, indicating that UV-induced phosphorylation is mediated through the ALK5 pathway (Appendix 1: Figure 3A). Additionally, these results made evident that in response to UV-irradiation, TGFβ signaling was induced, which was indicated via increased phospho-Smad2 levels (Appendix 1: Figure 3A). Similar experiments in which we transflect H1299 cells with wild type ΔNP63α or the phospho-ablative mutant ΔNP63α-AA, followed by UV-irradiation and A83-01 treatment demonstrated that UV-induced phosphorylation of ΔNP63α is mediated through induction of TGFβ and ALK5 signaling (Appendix 1: Figure 3B). These results are relevant to Task 3 as UV-irradiation initiates cellular stress and pro-survival responses; of which ΔNP63α has been shown to play a role in HNSCC (8) and triple negative breast cancers chemosensitivity (9).

Key Research Accomplishments

- Determined that TGFβ’s anti-clonogenic effects are mediated through ALK5-mediated phosphorylation of ΔNP63α.
- ΔNP63α is enriched in stem cells as indicated by ALDH activity and TGFβ treatment decreases the stem cell population in an ALK5 dependent manner.
- TGFβ-mediated phosphorylation of ΔNP63α is a destabilizing event.
- ALK5 directly phosphorylates ΔNP63α.
- ALK5-mediated phosphorylation of ΔNP63α requires TGFβR2.
- ALK5 intracellular fragment localizes to the nucleus to phosphorylate ΔNP63α in response to TGFβ stimulation.
- UV-induced phosphorylation of ΔNP63α is mediated through ALK5 signaling.

Reportable Outcomes

- Original paper publication:
Conclusion

To date, we have elucidated the mechanism by which TGFβ/ALK5 phosphorylates ∆NP63α. We have shown that this phosphorylation event is direct, and involves nuclear translocation of the intracellular portion of ALK5. Furthermore, we have demonstrated that TGFβ-mediated phosphorylation of ∆NP63α has significant effects on the stem cell activity (ALDH<sup>Hi</sup>), and is anti-clonogenic and causes an increase in G0/G1 cell cycle arrest. These results are significant as they describe a novel signaling pathway of TGFβ that involves ∆NP63α. Additionally, the anti-clonogenic and anti-stem cell effects of TGFβ, which are mediated via ∆NP63α, a destabilizing events, implicates ∆NP63α as a pro-tumorigenic factor, and brings to light a potential therapeutic strategy utilizing TGFβ to reduce ∆NP63α expression. As a result, we will continue to investigate the function of ∆NP63α phosphorylation as outlined in the tasks of the Approved Statement of Work.

References

Appendices

Phosphorylation of ΔNp63α via a Novel TGFβ/ALK5 Signaling Mechanism Mediates the Anti-Clonogenic Effects of TGFβ

Pratima Cherukuri1, Andrew J. DeCastro1,2, Amanda L. Balboni1,2, Sondra L. Downey1,2, Jennifer Y. Liu3, Justine A. Hutchinson1,2, James DiRenzo1,2*

1 Department of Pharmacology and Toxicology, The Audrey and Theodor Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America, 2 Program in Experimental Molecular Medicine, The Audrey and Theodor Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America, 3 Department of Biological Sciences, Dartmouth College, Hanover, New Hampshire, United States of America

Abstract

Genetic analysis of TP63 implicates ΔNp63 isoforms in preservation of replicative capacity and cellular lifespan within adult stem cells. ΔNp63α is also an oncogene and survival factor that mediates therapeutic resistance in squamous carcinomas. These diverse activities are the result of genetic and functional interactions between TP63 and an array of morphogenic and morphostatic signals that govern tissue and tumor stasis, mitotic polarity, and cell fate; however the cellular signals that account for specific functions of TP63 are incompletely understood. To address this we sought to identify signaling pathways that regulate expression, stability or activity of ΔNp63α. An siRNA-based screen of the human kinome identified the Type 1 TGFβ receptor, ALK5, as the kinase required for phosphorylation of ΔNp63α at Serine 66/68 (S66/68). This activity is TGFβ-dependent and sensitive to either ALK5-directed siRNA or the ALK5 kinase inhibitor AB3-01. Mechanistic studies support a model in which ALK5 is proteolytically cleaved at the internal juxtamembrane region resulting in the translocation of the C-terminal ALK5-intracellular kinase domain (ALK5IKD). In this study, we demonstrate that ALK5-mediated phosphorylation of ΔNp63α is required for the anti-clonogenic effects of TGFβ and ectopic expression of ALK5IKD mimics these effects. Finally, we present evidence that ultraviolet irradiation-mediated phosphorylation of ΔNp63α is sensitive to ALK5 inhibitors. These findings identify a non-canonical TGFβ-signaling pathway that mediates the anti-clonogenic effects of TGFβ and the effects of cellular stress via ΔNp63α phosphorylation.

Introduction

TP63 is a member of the p53 family of transcriptional regulators [1] that preserves long-term regenerative stasis in diverse epithelial structures by maintaining the replicative capacity of adult stem cells [2,3]. Several lines of evidence also implicate TP63 in multiple aspects of cancer initiation and progression. The mechanisms by which TP63 carries out these critical functions in development and disease are not fully understood, and progress toward this end is complicated by the fact that TP63 encodes as many as eight p63 isoforms. Differential usage of distal and proximal promoters results in isoforms with (TAp63) or without (ΔNp63) an amino-terminal trans-activation domain homologous to that of p53. Additionally alternative mRNA splicing results in C-terminal diversity. ΔNp63α is the predominant TP63 isoform in regenerative compartments of diverse epithelial structures and tumors of squamous epithelial origin. Isoform specific knockouts unambiguously indicate that ΔNp63α isoforms account for the maintenance of replicative capacity [4,5]. A second layer of complexity arises from studies indicating that ΔNp63α occupies greater than 5000 sites across the human genome and that these sites correlate with activation and repression of transcriptional targets [6]. Finally, the stability, transcriptional activity and cellular localization of TP63 gene products are regulated post-translationally by multiple phosphorylation events as well as by ubiquitination [7], SUMOylation [8] and ISGylation [9]. This combination of isoform diversity, widespread genomic occupancy, and post-translational regulation underscores the challenges of identifying the regulatory mechanisms and transcriptional targets of TP63 that account for its complex role in tissue and tumor stasis.

ΔNp63α has been shown to play important roles in cancer initiation and progression suggesting that pharmacologic strategies that disrupt the activity of ΔNp63α have the potential for therapeutic benefit. ΔNp63α is an oncogene that suppresses the activity of the Ink4a/ARF locus [10] and opposes the tumor suppressive effects of cellular senescence [11,12] suggesting a role in oncogenic initiation [13]. TP63 is amplified at the genomic level in 9.7% of head and neck squamous cell carcinomas, 12.9% of serous ovarian carcinomas, 23% of squamous cervical carcinomas and 28.5% of lung squamous cell carcinomas [http://chiportal].
org) [14]. Presently the relationship between this amplification and cancer initiation is unknown, however ΔNp63α is a survival factor that opposes a pro-apoptotic gene expression program [15,16] suggesting a correlation between TP63 amplification and therapeutic resistance. Other studies implicate ΔNp63α in cellular quiescence [17], which may account for the broad-spectrum resistance of squamous carcinomas [17], which may account for the broad-spectrum resistance to cytotoxic therapeutics. These studies implicate ΔNp63α in a diverse array of processes associated with cancer initiation and progression and this highlights the need to identify cellular signals governing these diverse activities.

TGFβ is a highly pleiotropic cytokine that governs diverse aspects of cell biology including cell cycle progression, senescence, differentiation and apoptosis [18,19]. Its effects are mediated through a heterotetrameric TGFβ receptor complex consisting of two molecules of the Type I TGFβ receptor (ALK5) and two molecules of the Type 2 TGFβ Receptor (TGFβR2) [20,21]. Both ALK5 and TGFβR2 possess intrinsic serine/threonine kinase activity, and upon ligand binding, TGFβR2 trans-phosphorylates ALK5 and enhances ALK5 kinase activity. This results in ALK5-mediated phosphorylation and nuclear translocation of the canonical effectors of TGFβ signaling, SMAD2 and SMAD3 [18]. In addition to this canonical TGFβ signaling pathway, the TGFβ receptor complex converges on several other cellular signaling pathways [22,23]. Recently, ChIP-Seq studies indicate that SMAD3 co-occupies genomic loci with transcription factors that are master regulators of diverse cell types including Oct4 in E5 cells, MyoD1 in myotubes and Pu.1 in the B-cell lineage [24] and may explain the cellular context-specific effects of TGFβ. TGFβ is also known for its regulation of postnatal mammary gland development and for its prominent role to act as a tumor suppressor by preventing mammary epithelial cell proliferation [25]. These studies implicate multiple signal transduction pathways in the pleiotropic effects of TGFβ.

The involvement of ΔNp63α in cancer initiation and progression suggests that signaling pathways that govern ΔNp63α activity or stability may be targeted for therapeutic benefit. Multiple phosphorylation sites have been identified within ΔNp63α and other TP63 isoforms [26–29] however, the underlying signaling pathways and functional consequences are known for only a subset of these modifications. In response to cisplatin, ΔNp63α is phosphorylated by c-Abl and this is required for cell viability. This phosphorylation event suggests that phosphorylation at S66/68 might mediate a mitogenic response to cellular stress in which stem cells respond by dividing to produce new progenitors. To identify the cellular signaling pathways that promote S66/68 phosphorylation, an siRNA-based screen of the human kinome was conducted. The Type 1 TGFβ Receptor, ALK5, was identified as a kinase that is necessary for phosphorylation of ΔNp63α at S66/68. Consistent with this finding, TGFβ was sufficient to cause phosphorylation of ΔNp63α, and selective inhibitors of the ALK5 kinase blocked this phosphorylation. Mechanistic studies support a model in which TGFβ stimulation initiates the proteolytic cleavage of ALK5 within the juxtamembrane resulting in the nuclear translocation of ALK5IKD. This translocation results in the phosphorylation of ΔNp63α, which is required for the anti-clonogenic activities of TGFβ. Consistent with this model, ectopic expression of ALK5 is sufficient to phosphorylate ΔNp63α and recapitulates the anti-clonogenic and anti-proliferative effects of TGFβ. Finally, we show that phosphorylation of ΔNp63α at S66/68 in response to ultraviolet (UV) irradiation is mediated by ALK5 indicating that the ALK5/ΔNp63α signaling pathway may mediate aspects of the cellular response to stress. Together these studies identify ΔNp63α as a target of a novel non-canonical ALK5 signaling pathway that mediates cellular responses to TGFβ.

Materials and Methods

Cell Culture and Treatments

Immortalized Mammary Epithelial Cells (IMECs) [32] were cultured in MEGM complete media (Lonza CC-3051) with 50 μg/ml puromycin and Penicillin/Streptomycin. Treatments with TGFβ1 and A83-01 were performed in basal MEGM media with 50 μg/ml puromycin, 0.1%BSA and Penicillin/Streptomycin on 20% confluent cells plated the night before, H1299s (ATCC# CRL-5803) were cultured in Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% FBS and Penicillin/Streptomycin. All TGFβ1 and A83-01 treatments of H1299 cells were performed in DMEM media supplemented with 0.1% BSA and Penicillin/Streptomycin. Recombinant TGFβ1 (R&D systems) was used at a 500 pM concentration for 1 hr or as indicated. The ALK5 kinase inhibitor, A83-01 (Tocris), was used at a concentration of 2 uM for 1 hr prior to TGFβ1 treatment, or as indicated. For UV experiments, cells plated at 30% confluence were treated with UV radiation at 50 J/m² and lysates were harvested 1 hr later. For stability experiments, cells were plated at 30% confluence and treated with 20 μg/ml cycloheximide (CHX).

Plasmids and Transfections

The expression construct pDNA3.1-ΔNp63α-WT was generated as previously described [33]. pDNA3.1-ΔNp63α-AA (phospho ablative mutant) was made via the conversion of the amino acid serine to alanine (SSA) at positions 66 and 68 of the DNA binding domain of TP63 using the Statagene Quik Change II site-directed mutagenesis kit (Cat# 200523-5) with the following set of primers;

- sense primer 5'-CGATGGCTCTCGGCTGGACGACCCGC-CATGCCCTCC-3', and
- antisense primer 5'-GGAGGG-GAGTGGCGGTTGCTGGAGGAGAGACATCG-3'. TGFβRI expression constructs: pRK5 TGFβRI wt Flag, pRK5 TGFβRI (T202D) Flag, and pCMV5B- TGFβRI (K222R) were purchased from Addgene (Cambridge, MA) and were used as previously described [34]. pRK5- TGFβRII Flag expression vector [21] was purchased from Addgene (Cambridge, MA). The TGFβRII-GFP plasmid was a kind gift from Dr. J. C. Zwaagstra (McGill University, Canada). pcDNA3.1- TGFβRIK20 was generated by PCR amplification of the kinase domain region of the pRK5 TGFβRI wt-Flag plasmid using the following primers designed to incorporate NheI and HindIII overhangs; sense primer 5'-GAATGCGTAGCATGGATGTGTGCTAACAAAGAGCATC-3' and the antisense primer 5'-GAT-CAAGCTTTGTGCTGCTGCTGCTTGTAGTC-3'. Fragments generated from PCR were then cloned into the pcDNA3.1 vector. All plasmid transfections were carried out using Lipofectamine2000 (Invitrogen, Cat#11668) according to manufacturers protocol.

Kinome Screen

The Silencer Select Human Kinase siRNA Library (Catalog# 4399718) from Ambion was used to perform a genome wide kinome screen. The assay was performed in a 96 well format. Three different siRNAs for a single gene were co-transfected per
well at a concentration of 0.5 pmoles using siPORT NeoFX Transfection Agent (Cat.#AM4511). Forty-eight hours post siRNA transfection; cells were infected with ΔNp63α-WT adenovirus resulting in 90% infection efficiency. Quantitative immunofluorescence assays were then performed using the anti-phospho-p63 (Ser160/162) antibody. Immunofluorescence assays were performed as described below. Fluorescent values were obtained using the Molecular Devices Gemini XS Fluorescent Microplate Reader (EX: 540, EM: 570 and Cutoff: 570). Raw fluorescence values were normalized against total cell count, three different negative controls and a positive control. To obtain total cell count, cells after IP readings were stained with crystal violet. After a rigorous wash with distilled water, stain from the cells were eluted in a 20% methanol and 10% acetic acid solution, values were read at 595 nm using the Molecular Devices Thermo Max Microplate reader at 595 nm.

Small-interfering RNA (siRNA) Transfection
Silencer select pre validated small-interfering RNA against TGFβRI and TGFβRII (Catalog #: 4390824) were purchased from Ambion. Ambion’s siPORT NeoFX Transfection Agent was used in all siRNA transfections according to the manufacturer’s protocol. Ambion Silencer®Negative Control #2 siRNA (Cat.#AM4613) was used as control for all siRNA transfections. Forty eight hours post siRNA transfection, cells were transfected with GFP, ΔNp63α-WT or ΔNp63α-AA mutant plasmids, and harvested 24 hrs after plasmid addition in 1X SDS lysis buffer for further analysis by immunoblotting.

Western Analysis and Immunofluorescence
Cells were lysed in 1X SDS lysis buffer with β-mercaptoethanol and were resolved by 10% SDS-PAGE. Antibodies used for western and Immunofluorescence were anti-p63 clone 4A4 (Sigma, Cat.#P5737) for total P63, anti-phospho-p63 (Ser160/162) (Cell signaling, Cat.#4981), anti-phospho-Smad2 (Ser465/467) (Cell signaling, Cat.#3100), anti-Smad2 (Cell signaling, Cat.#3122), anti-GFP (Invitrogen, Cat.#G7121), anti-TGFβ RII (L-21) (Santa Cruz, Cat.#sc-400), anti-TGFβ RI (V-22) antibody from (Santa Cruz, Cat.#sc-398) and anti-β-Actin antibody from (Cell signaling, Cat.#3700). All primary antibodies were detected with their respective secondary HRP-conjugated antibodies using Millipore chemiluminescence. Primary antibodies for Immunofluorescence assays were detected with either anti-mouse-Alexa Fluor 488 (Invitrogen#A11029) or anti-rabbit-Alexa Fluor 555 (Invitrogen#A21429).

Colony Formation Assay
IMEC cells were plated at 1000 cells per well in a 6-well dish. Cells were fed every other day with TGFβ1± A83-01 for 10–14 days. Cells transfected with p63 constructs were selected for in the presence of G418. Colonies were fixed in ice-cold 80% methanol and stained with 0.3% crystal violet.

In vitro Kinase Assay
Recombinant ALK5 kinase was produced by transfecting H1299 cells with an expression vector programmed to produce C-terminally flag-tagged ALK5 Receptor. Immunoprecipitation of the Flag-tagged ALK5 kinase was performed using Peirce Classic IP kit and monoclonal ANTI-FLAG M2 antibody(Sigma Cat # F1804). Recombinant ALK5 was eluted from beads by incubation with 100 µg/ml of soluble flag peptide (Sigma Cat # F2920) in 10 mM Tris, 150 mM NaCl, pH7.4 buffer. GST-ΔNp63α was produced via IPTG induced expression in Y1090 cells. Bacteria were collected by centrifugation and lysed by sonication in the presence of a cocktail of protease inhibitors. Lysates were cleared by centrifugation and GST-ΔNp63α was enriched on glutathione-sepharose beads. For the kinase reaction either 1 or 5 µL of soluble ALK5 was added to fixed amounts of GST-ΔNp63α bound to beads in 1X kinase buffer (50 mM HEPES, 5 mM MgCl2, 1 mM CaCl2) with 10 mM ATP. Reactions were incubated at 30°C for 30 min. Reactions were stopped by the addition of 2× SDS Sample Buffer and western blots were done as described previously.

Aldefluor Assay
ALDHhigh and ALDHlow populations in IMEC cells were identified using the Aldefluor assay kit (Stem Cell Technologies). IMEC cells were plated at 25% confluence and treated with Vehicle, TGFβ1 or A83-01 for 24 and 48 hours. Cells were then harvested and stained with ALDEFLUOR reagent as per the manufacturer’s protocol.

Cell Cycle Analysis and Subcellular Fractionation
Cells were collected by trypsinization and gentle centrifugation before being re-suspended in ice cold PBS. An equal volume of ice cold 80% methanol was added with gentle vortexing and cells were fixed on ice for 30 minutes. Fixed cells were collected by centrifugation and re-suspended in PBS supplemented with 1% cold 80% methanol and 1% NP40. After 45 minutes at 37°C, cells were stained with propidium iodide and samples were analyzed on a BD FACScan instrument. Nuclear and cytoplasmic extracts were prepared using the EpiQuikTM Nuclear Extraction Kit I according to the manufacturer’s protocol.

Results

A Small Interfering RNA Screen of the Human Kinome Identifies ALK5 as a Putative ΔNp63α Kinase
To identify the signaling pathways governing the diverse activities of ΔNp63α a siRNA-based screen of the human kinome was carried out in H1299 lung adenocarcinoma cells (Figure S1). H1299 cells do not express ΔNp63α but rapidly phosphorylate ectopic wild-type ΔNp63α (ΔNp63α-AA) but not a mutant allele in which serines at positions 66 and 68 were changed to alanine (ΔNp63α-AA) (Figure 1A). Pools of three kinase-specific siRNAs were transfected into H1299 cells. At 48 hours post transfection cells were infected with an adenovirus programmed to express ΔNp63α. Twenty four hours post infection, phospho-p63 levels were measured by immunofluorescence and quantitated using a fluorescent plate reader. Following this analysis, cells were stained with crystal violet to record cell density. Analysis of phospho-ΔNp63α immunofluorescence intensity normalized to cellular DNA (Figure 1B) resulted in the identification of several kinases (Table in Figure S1) with normalized phospho-ΔNp63α scores lower than the negative control (red dashed line). Among these was the Type 1 TGFβ Receptor (ALK5) and transfection of each of the three individual ALK5-directed siRNAs was sufficient to suppress ΔNp63α phosphorylation at S66/68, indicating that ALK5 was necessary for ΔNp63α phosphorylation (Figure 1C). To determine if ALK5 was sufficient to phosphorylate ΔNp63α H1299 cells were transfected flag-tagged ALK5 and recombinant ALK5 was isolated by anti-flag affinity chromatography and eluted with soluble flag-peptide. One and five µL of the eluted fraction was incubated with increasing amounts of bacterially expressed glutathione-S-transferase-ΔNp63α fusion protein. Western analysis revealed that recombinant ALK5 was able to phosphorylate ΔNp63α in vitro (Figure 1D). Given that both ALK5 and GST-ΔNp63α were affinity purified, these data support the assertion...
that ALK5 directly phosphorylates ΔNp63α. This in turn raises questions regarding the mechanisms by which a membrane-bound kinase can phosphorylate a nuclear protein. Finally, H1299 cells were co-transfected with ΔNp63α and a series of ALK5 expression plasmids that express wild type or mutant ALK5. Phospho-p63 western analysis indicated that ectopic ALK5 resulted in phosphorylation of ΔNp63α. Remarkably, a threonine to aspartate mutation T202D (T198D in rat ALK5 NP_036907.2) that constitutively activates TGFβ signaling [34] caused an increase in SMAD2 phosphorylation but was unable to phosphorylate ΔNp63α. Additionally a lysine to arginine mutation K232R (K226R in rat ALK5 NP_036907.2) in rat ALK5 that fails to mediate canonical TGFβ signaling [35] and fails to phosphorylate SMAD2 but is able to efficiently phosphorylate ΔNp63α (Figure S2). These observations suggest that the intramolecular determinants of SMAD2 phosphorylation, and by extension canonical TGFβ-signaling, are distinct from those required for ΔNp63α phosphorylation. Together these studies demonstrate that ALK5 is necessary and sufficient for ΔNp63α and suggest that the molecular mechanisms by which ALK5 phosphorylates ΔNp63α may be distinct from those governing phosphorylation of SMAD2.

TGFB Stimulates ALK5-mediated Phosphorylation of ΔNp63α via TGFB2

The finding that ALK5 is necessary and sufficient for ΔNp63α phosphorylation suggested that TGFβ-signaling governs ΔNp63α phosphorylation. We therefore sought to determine if TGFβ stimulation was sufficient to enhance ΔNp63α phosphorylation. For these studies, an hTERT-immortalized mammary epithelial cell (IMEC) line was used due to its robust expression of ΔNp63α [32] and the fact that it is cultured in a chemically-defined media, which enables experimentation under TGFβ-depleted conditions. Results indicate that TGFβ stimulation increases phospho-ΔNp63α levels within one hour, indicating signaling kinetics similar to SMAD2 phosphorylation. This phosphorylation was inhibited by A83-01, a selective ALK5 kinase inhibitor [36] (Figure 2B), which supports the assertion that TGFβ mediated ΔNp63α phosphorylation requires ALK5 activity. This observation coupled to the fact that ALK5 possesses no inherent TGFβ-binding capacity suggested the involvement of TGFB2. siRNAs that produce a substantial reduction in TGFB2 expression (Figure S3) directed against TGFB2 R2 were co-transfected into IMECs ± pcDNA-ΔNp63α. Phospho-p63 western analysis indicated that TGFB2 R2 is necessary for TGFβ-mediated phosphorylation of ΔNp63α and SMAD2 (Figure 2C).

Figure 1. An siRNA-based screen of the human kinome identifies ALK5 as a putative ΔNp63α kinase. A. ΔNp63α-WT and phospho-ablative p63 mutant (ΔNp63α-AA) were transiently transfected into H1299 cells. Cell lysates were harvested after 24 hrs and the levels of phospho-p63, total p63 and β-actin were analyzed. B. Graphical representation of results of the phospho-p63 expression as indicated by normalized fluorescent values from the kinome screen. Each dot represents relative p-p63 abundance following treatment with siRNA (n = 3) directed against a single kinase. The green dashed line represents mean positive control value and the red dashed line represents the mean negative control. The blue dashed line represents the mean phospho-p63 score in the screen. All the hits below the red dotted line were considered as possible kinases responsible for phosphorylating ΔNp63α. C. Three different siRNAs targeted against ALK5 were transfected into H1299 cells, 48 hrs later cells were transfected with either GFP, ΔNp63α-WT or ΔNp63α-AA expression vectors, whole cell lysates harvested after 24 hrs were analyzed for phospho-p63, total p63, and β-actin. D. Recombinant ALK5 phosphorylates ΔNp63α in vitro. Purified GST tagged ΔNp63α protein was incubated with purified Flag-ALK5 kinase for 30 min at 30°C and reactions were analyzed for phospho-p63, total p63, and Flag-ALK5.

doi:10.1371/journal.pone.0050066.g001
Whole cell extracts were analyzed after 1 hr for phospho-p63, total-p63, phospho-SMAD2 and β-actin via immunoblotting. C. SiRNA targeted against TGFβR2 was transfected into IMEC cells, 48 hrs later cells were transfected with ΔNp63α expression vector or GFP control vector. Whole cell lysates were harvested 24 hrs later and analyzed for phospho-P63, total-P63, phospho-SMAD2 and β-actin. D. Ectopic expression of ALK5 and TGFβR2 is sufficient to phosphorylate ΔNp63α in a manner that is independent of TGFβ.

doi:10.1371/journal.pone.0050066.g002

Figure 2. TGFβ stimulates of ALK5-mediated phosphorylation of ΔNp63α via TGFβR2. A. IMEC cells were treated with the indicated concentrations of TGFβ1 ligand for 1 hr. Whole cell lysates were harvested and analyzed by immunoblotting for levels of phospho-p63, total p63, phospho-SMAD2 and β-actin. B. ALK5-mediated phosphorylation of ΔNp63α is inhibited by A83-01. IMEC cells were treated with A83-01 at the indicated concentrations 1 hr prior to TGFβ1 treatment.

ALK5 Mediates Phosphorylation of ΔNp63α in Response to Ultraviolet Irradiation

Previous studies have shown that ΔNp63α is phosphorylated at Ser66/68 in response to ultraviolet (UV) irradiation [29]. Other studies have demonstrated increased TGFβ signaling in response to UV irradiation [38–40]. Additionally, recent studies have implicated TGFβ signaling in increased metastasis following ionizing radiation [41] and others have shown that ionizing radiation results in enhanced TGFβ signaling from the tumor microenvironment that results in pro-carcinogenic effects [42]. Together these studies indicate that ALK5 signaling mediates ΔNp63α phosphorylation in response to UV irradiation. To determine if ALK5 mediates UV-induced phosphorylation of endogenous ΔNp63α, IMECs were incubated in the presence or absence of A63-01 for 12 hrs and then subjected to UV irradiation. Western analysis indicated that UV irradiation stimulated phosphorylation of ΔNp63α was sensitive to A83-01, indicating that ALK5 was able to phosphorylate ΔNp63α in response to UV irradiation (Figure 3A). Interestingly, UV irradiation also increased phosphorylation of SMAD2 in a manner that was sensitive to A83-01 suggesting that the mechanism(s) by which UV irradiation induces TGFβ-signaling most likely act upstream of ALK5. Similarly, H1299 cells were transfected with GFP, ΔNp63α-WT or the phospho-ablative mutant, ΔNp63α-AA, and cells were either mock exposed or exposed to UV irradiation followed by treatment with A83-01 or vehicle. Western blot analysis indicated that phosphorylation of ΔNp63α at Ser66/68 increased in response to UV irradiation and that inhibition of ALK5 with A83-01 was sufficient to ablate ΔNp63α phosphorylation (Figure 3B). Together these studies indicate that ALK5 mediates UV-induced activation of TGFβ-signaling which leads to increased phosphorylation of SMAD2 and ΔNp63α. These studies implicate ALK5 in a previously unknown role in the cellular stress response and suggest that disruption of ΔNp63α phosphorylation may sensitize cells to diverse types of cellular stress. Coupled to studies indicating that ΔNp63α is a potent blockade to apoptosis in experimental models of HNSCC [16] and triple negative breast cancer [15] these studies identify a potential strategy to subvert ΔNp63α mediated drug resistance by inhibiting TGFβ signaling.

Nuclear Accumulation of the Intracellular Kinase Domain of ALK5 (ALK5ΔK) in Response to TGFβ

The identification of ALK5 as a ΔNp63α kinase and the demonstration that this event is initiated by TGFβ raised significant questions regarding the mechanisms by which a
membrane bound kinase phosphorylates ∆Np63α, which is located in the nucleus. ALK5 activation is propagated through multiple transduction pathways, several of which rely upon diverse kinase activities [43–45]. To determine if any of these known pathways mediate ∆Np63α phosphorylation, phospho-∆Np63α immunofluorescence data from the kinome-wide siRNA screen was re-evaluated. Results of this evaluation indicated that no other kinase known to be downstream of ALK5 was implicated in ∆Np63α phosphorylation (Figure S4). Additionally, western analysis of IMECs transfected with ALK5 siRNA identified a 34-kDa fragment that was sensitive to ALK5-directed siRNA and detectable with a antisera directed against the C-terminus of ALK5 (Figure 4A). The 34-kDa size coupled to selective detection with a C-terminally directed antibody suggested that this band is the product of proteolytic cleavage of ALK5 at or near the intracellular juxtamembrane region. To test this hypothesis, a plasmid encoding C-terminally-flag-tagged versions of wild-type ALK5 was transfected into H1299 cells and flag-tagged proteins were detected by western blot. Results indicated that ectopic expression of ALK5 results in a 56 kDa full-length receptor and a 34 kDa C-terminal fragment (Figure 4B) suggesting that exogenous ALK5 was processed in a manner that is similar or identical to endogenous ALK5. Since these experiments were done by transfecting cDNAs of wild-type and mutant ALK5, these results also demonstrate that the 34-kDa fragment is unlikely to be the result of alternative mRNA splicing. These observations support a model in which TGFβ stimulates proteolytic cleavage of ALK5 and that the 34 kDa ALK5 intracellular kinase domain (ALK5IC) would preferentially localize in the nucleus. Western analysis of nuclear and cytoplasmic extracts from IMECs indicated that the 34-kDa ALK5 C-terminal fragment was selectively localized to the nucleus (Figure 4C). To determine if ALK5 is able to translocate to the nucleus, an ALK5-GFP fusion expression vector [46] was transfected into IMECs under TGFβ-depleted conditions and cells were then stimulated with vehicle or TGFβ. Fluorescence microscopy indicated that TGFβ stimulated the redistribution of ALK5-GFP to the nucleus, consistent with the nuclear localization of the ALK5ICKD (Figure 4D). Similarly, stimulation of H1299 cells with TGFβ resulted in redistribution of ALK5 from the cytoplasm to the nucleus (Figure 4E). Transfection of ALK5-directed siRNA confirms the specificity of the immunofluorescent analysis (Figure S5). Together these observations support a mechanistic model in which TGFβ stimulation initiates the nuclear translocation of ALK5, thereby enabling phosphorylation of ∆Np63α.

TGFβ is Anti-proliferative and Suppresses ALDH1 Activity and ∆Np63α Protein Levels in a Mammary Stem Cell Model

The hTERT immortalized mammary epithelial cells (IMECs) were derived via retroviral transduction of the catalytic subunit of human telomerase (hTERT) into primary human mammary epithelia and clones were selected for their ability to bypass replicative senescence [32]. Subsequent analysis of multiple clonal IMEC lines indicated a basal/myoepithelial cytokeratin profile and robust expression of ∆Np63α. Other studies indicated that IMECs possess developmental potency based upon their ability to produce acinar structures with biochemically distinct basal and luminal layers [47]. Based upon these similarities to mammary stem cells, we sought to understand the biological effects of TGFβ on IMECs and to determine the degree to which phosphorylation of ∆Np63α contributes to these effects. TGFβ caused a significant decrease in cell number over 72 hours, and this effect was reversed by co-treatment with A83-01 (Figure 5A). Cell cycle distribution analysis indicated a decrease in the population of cells in S-phase in response to TGFβ and a corresponding increase of cells in S-phase in response to A8301 (Figure 5B). To address the effects of TGFβ on stem cell activity, IMEC sub-populations with features of stem cells were enriched on the basis of high aldehyde dehydrogenase 1 (ALDH1) activity [48]. Analysis of ∆Np63α mRNA levels in ALDH1high and ALDH1low fractions indicated that ∆Np63α mRNA levels were significantly enriched in the ALDH1high self-renewing population (Figure 5C). This enrichment for ∆Np63α expression is consistent with the assertion that ALDH1high fractions of IMECs are enriched for self-renewing capacity and also indicates that TGFβ may influence this fraction via ∆Np63α phosphorylation. To test this, IMECs were treated with vehicle, TGFβ or A83-01 for 24 and 48 hours, and the ALDH1high fraction was measured. Results indicated that TGFβ treatment significantly reduced ALDH1 activity in IMECs resulting in a smaller ALDH1high cellular fraction (Figure 5D and Figure S6) The reduction in ALDH1high cells in response to

![Figure 3. ALK5 mediates phosphorylation of ∆Np63α in response to ultraviolet irradiation. A. IMEC cells were plated and treated with the indicated amounts of A83-01 or vehicle for 12 hrs after which cells were exposed to 50 J/m² UV radiation. Whole cell lysates were collected after 1 hr of UV treatment and analyzed by immunoblotting for phospho-P63, total-P63, phospho-SMAD2 and β-actin levels. Phospho-SMAD1/5/8 was used as a control to show that there were no off-target effects for A83-01 at the concentrations used. B. H1299 cells were transfected with GFP, ∆Np63α-WT or ∆Np63α-AA expression vectors and cells were treated with 2 μM A83-01 or vehicle control. Twenty-four hours later cells were exposed to 50 J/m² UV radiation and whole cell extracts were collected after 1 hr to analyze the levels of phospho-P63, total-P63 and β-actin by immunoblotting.](doi:10.1371/journal.pone.0050066.g003)
TGFβ, coupled to the fact that DNp63α expression is increased in this fraction suggested that TGFβ might be opposing the activity of DNp63α. Together these data indicate that TGFβ signaling in IMECs is anti-proliferative and targets self-renewing populations that are enriched for DNp63α expression.

The previous data suggests that TGFβ opposes the activity or expression of DNp63α. This coupled to previous studies indicating that phosphorylation of DNp63α at S66/68 leads to its destabilization suggested that TGFβ might oppose DNp63α by causing its degradation. To test this, IMECs were treated with TGFβ or A83-01 in the absence or presence of cycloheximide. Under these conditions treatment of IMECs with TGFβ for 4 hours in the absence of de novo protein synthesis selectively repressed DNp63α protein levels indicating that TGFβ may destabilize DNp63α (Figure 6A). To determine if the phosphorylated form of DNp63α was preferentially destabilized, cells were pre-treated with vehicle, TGFβ or A83-01 for 1 hour followed by treatment with vehicle or cycloheximide for 4 hours and phospho-p63 levels were evaluated by western blot. Consistent with data in Figure 2, TGFβ stimulation leads to increased phosphorylation of DNp63α, however, treatment with cycloheximide resulted in the destabilization of phospho-p63 signal in the TGFβ-treated sample, indicating that TGFβ-mediated phosphorylation of DNp63α destabilizes DNp63α (Figure 6B). To determine if TGFβ-stimulated degradation of DNp63α was mediated by the 26S proteasome, H1299 cells were transfected with GFP, ΔNp63α-WT and ΔNp63α-AA under conditions that actively promoted TGFβ signaling. Cells were then treated for 2 hours with vehicle or 1 μM MG-132. Western analysis showed that phosphorylated DNp63α was stabilized by MG-132 indicating that phosphorylated DNp63α is degraded by the 26S proteasome. Western analysis for total DNp63 indicated that MG132 caused an increase in ΔNp63α-WT but not in ΔNp63α-AA, indicating that targeting of DNp63α to the 26S proteasome requires phosphorylation of serines 66 and 68. These findings support a model in which TGFβ-mediated phosphorylation of ΔNp63α leads to its degradation by the 26S proteasome.

The Anti-clonogenic Effects of TGFβ Require Phosphorylation of ΔNp63α

TGFβ signaling has been shown to be a tumor suppressive during early stages of breast cancer initiation and to promote breast cancer progression and metastasis at later stages [18]. The specific targets and signaling pathways governing these divergent effects are incompletely understood. The previous results indicate that TGFβ signaling is growth inhibitory and destabilizes ΔNp63α...
via phosphorylation. To determine if phosphorylation of ΔNp63α is required for the anti-proliferative effects of TGFβ, IMECs were transfected with GFP, ΔNp63α-WT or ΔNp63α-AA and selected in G418 while simultaneously being treated with either TGFβ1 or A83-01 for the indicated time points. Dashed lines flank the S-phase region. IMEC cells were sorted based on the ALDH staining. ΔNp63α mRNA expression levels were analyzed using quantitative PCR. IMEC cells expressing ALDH high and low were analyzed after treating IMEC cells with vehicle control, TGFβ1 and A83-01 at the indicated time points. IMEC cells were treated with control or cycloheximide (CHX) for 2 hrs and then treated with TGFβ1 or A83-01 for 2 hrs. Whole cell lysates were analyzed for ΔNp63α and β-actin. IMEC cells were treated with control, TGFβ1 and A83-01 for 1 hr, after which cells were treated with control and CHX for 4 hrs. Whole cell lysates were analyzed for Phospho-p63 and β-actin.

Figure 5. TGFβ is anti-proliferative and suppresses ALDH1 and ΔNp63α protein levels activity in a mammary stem cell model. A. Cell counts plotted for IMEC cells treated with control, TGFβ1 and A83-01 for the indicated time points. Data are representative of multiple B. Cell cycle analysis was performed by PI staining on IMEC cells after treatment with control, TGFβ1 or A83-01 for the indicated time points. Dashed lines flank the S-phase region. C. IMEC cells were sorted based on the ALDH staining, ΔNp63α mRNA expression levels were analyzed using quantitative PCR. D. IMEC cells expressing ALDH high and low were analyzed after treating IMEC cells with vehicle control, TGFβ1 and A83-01 for 1 hr, after which cells were treated with control and CHX for 4 hrs. Whole cell lysates were analyzed for Phospho-p63 and β-actin.

doi:10.1371/journal.pone.0050066.g005

ALK5 Mediates Phosphorylation of ΔNp63α

PLOS ONE | www.plosone.org 8 November 2012 | Volume 7 | Issue 11 | e50066
ALK5 Mediates Phosphorylation of ΔNp63α

We report the identification of the Type 1 TGFβ Receptor, ALK5, as a kinase that mediates phosphorylation of ΔNp63α at S66/68. Our studies indicate that TGFβ stimulation and UV irradiation also phosphorylate ΔNp63α at S66/68 and this effect is sensitive to pharmacologic inhibition of ALK5 with A83-01. We present data indicating that TGFβ is able to stimulate the nuclear translocation of ALK5 and that a 34 kDa C-terminal truncation of ALK5 preferentially translocates to the nucleus. Our studies indicate that the anti-clonogenic effects of TGFβ are mediated by ALK5KD and require phosphorylation of ΔNp63α.

Additional studies will be necessary to determine the degree to which this pathway accounts for the effects of TGFβ on the activity of adult stem cells. Previous studies have shown that TGFβ promotes oncogene-induced senescence (OIS) in a manner that is independent of p53 [49]. Separately ΔNp63α has been shown to be a potent suppressor of OIS [13]. Here we present data indicating that TGFβ/ALK5/ΔNp63α signaling may contribute to the proliferative capacity of adult stem cells and tumor stem cells. Together these studies describe a previously unrecognized TGFβ signaling pathway that directly impacts the proliferative capacity and clonogenicity of ΔNp63α-positive cells. Additional studies will be necessary to determine the cellular consequences of TGFβ-mediated phosphorylation of ΔNp63α.

Previous studies have shown that ΔNp63α is phosphorylated at S66/68 in response to UV irradiation [29]. The observation that UV-initiated phosphorylation of ΔNp63α was sensitive to A83-01 implicates ALK5 in the cellular response to stress, however, additional studies will be necessary to determine if ALK5-mediated ΔNp63α phosphorylation contributes to the role of TGFβ signaling in promoting metastasis following ionizing radiation [41]. Similarly, it will be of significant interest to determine if the potent TGFβ response of the tumor microenvironment to radiation [42] contributes to ΔNp63α phosphorylation.

Discussion

IMECs. Consistent with the proposed model, ectopic ALK5KD accumulates in the nucleus (Figure 6B) and phosphorylates ΔNp63α in a manner that is independent of TGFβ but sensitive to A83-01 (Figure 6C). The observation that ectopic ALK5KD is sufficient to phosphorylate ΔNp63α under TGFβ-depleted conditions is consistent with a model in which TGFβ signaling is bypassed by directly targeting ALK5KD to the nucleus. This observation predicts that ALK5KD is sufficient to recapitulate the anti-clonogenic effects of TGFβ. IMECs were transfected with expression plasmids encoding ALK5KD and either ΔNp63α-WT or ΔNp63α-AA. G418 resistant colonies were selected and quantified. Results indicated that ALK5KD was potently anti-clonogenic (Figure 6D) and that this effect was partially rescued by ΔNp63α-WT and completely rescued by ΔNp63α-AA (Figure 6E). These results confirm that the anti-clonogenic effects of TGFβ in IMECs are mediated by ALK5KD and require phosphorylation of ΔNp63α. These studies identify ΔNp63α as a novel target of TGFβ signaling and indicate that the ability of ΔNp63α to promote colony formation is potently inhibited by TGFβ.

Figure 6. TGFβ treatment destabilizes ΔNp63α in a manner that is dependent upon the kinase activity of ALK5. A. TGFβ increases the rate of ΔNp63α turnover. IMECs were treated with vehicle or cycloheximide followed by treatment with vehicle, TGFβ or A8301. B. TGFβ stimulation selectively increases the rate of turnover of phospho-ΔNp63α. IMECs were treated with vehicle, TGFβ or A83-01 followed by vehicle or cycloheximide. C. Phospho-p63 is stabilized by the 26S proteasome inhibitor MG132. H1299 cells were transfected with GFP, ΔNp63α WT and ΔNp63α AA and treated for 2 hours with 1 μM MG132. doi:10.1371/journal.pone.0050066.g006
Coupled to the finding that TGFβ-mediated phosphorylation of ΔNp63α is anti-proliferative and anti-clonogenic, the ALK5-mediated response to cellular stress may act as a protective mechanism that limits proliferation under conditions of cellular or genotoxic stress. Additional studies will be necessary to determine if the mechanisms underlying activation of ALK5 in response to cellular stress are TGFβ-dependent or TGFβ-independent. Furthermore, it will be potentially clinically relevant to determine the biological consequences of ALK5-mediated phosphorylation of ΔNp63α in enriched tumor stem cell fractions. Finally, ΔNp63α has been shown to act as a survival factor that mediates therapeutic resistance and opposes apoptosis in breast cancers with a basal phenotype [15] and also in squamous cell carcinomas of the head and neck [16]. It will be of interest to determine if disruption of the TGFβ/ALK5/ΔNp63α signaling pathway subverts these activities thereby overcoming therapeutic resistance.

Recently, several studies have indicated unacceptable levels of cardiac and inflammatory toxicity associated with selective ALK5 kinase inhibitors and it is likely that these adverse effects will limit their development and clinical utility [32]. Given the remarkably pleiotropic actions of TGFβ, it is not surprising that drugs that disrupt all ALK5 signaling would have a wide range of effects. This highlights the need to identify specific signaling pathways downstream of TGFβ that account for specific activities of TGFβ. Doing so will make it possible to target specific actions of TGFβ while avoiding adverse side effects. Data presented here support a model in which unknown proteolytic activity mediates the translocation of ALK5IKD. This implies that inhibition of this protease may result in disruption of ΔNp63α phosphorylation. Further studies will be necessary to identify this protease, however a recent study has shown that the TNF-α Converting Enzyme (TACE) is able to mediate proteolysis of ALK5 and that TACE activity is required for accumulation of ALK5 in the nucleus [33]. The specific relevance of this finding to the generation of ALK5IKD and phosphorylation of ΔNp63α is unknown because in that study TACE was shown to target the ALK5 ectodomain, which is predicted to produce a fragment greater than 34 kDa. This also raises questions regarding the mechanism(s) by which an ALK5 fragment that retains the transmembrane domain might translocate to the nucleus. Presently the protease(s) that account

Figure 7. The anti-clonogenic effects of TGFβ require phosphorylation of ΔNp63α. A. IMEC cells were transiently transfected with GFP, ΔNp63α-WT or ΔNp63α-AA at equimolar ratios. 48 hrs after transfection cells were subjected to G418 selection with control, TGFβ1 or A83-01. Colonies formed were then stained with crystal violet. To quantify colonies 3 randomly 1 cm² spaces per well were counted and these data were used to calculate the average number of colonies per cm². Error bars represent the standard deviation. A two-tailed T-Test was used to determine the significance of the effects of TGFβ1 or A83-01 for 1 hr and whole cell lysates were analyzed for phospho-P63, totalP63, phospho-SMAD2, total SMAD2 and β-actin via immunoblotting. B. IMEC cells were transfected with GFP or ALK5KD at equimolar ratios. 48 hrs after transfection cells were subjected to G418 selection and visible colonies formed were then stained with crystal violet. C. IMEC cells were either transfected with GFP, ALK5KD, ΔNp63α-WT and ΔNp63α-AA or ALK5KD, ΔNp63α-AA and ALK5KD, ΔNp63α-WT at equimolar ratios. 48 hrs after transfection cells were subjected to G418 selection. Formed colonies were then stained with crystal violet.

doi:10.1371/journal.pone.0050066.g007
for generation of ALK5<sup>IKD</sup> remain unknown and their identification represents an important step in testing our model for ALK5-mediated ΔNp63α phosphorylation and also in identifying pharmacologically accessible pathway components.

Supporting Information

**Figure S1** Schematic representation of the siRNA-based screen of the human kinome. The table at the bottom lists the top 14 hits in the screen showing the data produced from fluorescence plate readings of the IF and subsequent Abs<sub>600</sub> readings for crystal violet staining. Primary hits progressed to the secondary screen and kinases for which all three siRNAs repressed phosphorylation of DNp63α were selected.

(PDF)

**Figure S2** The molecular determinants of DNp63α phosphorylation by ALK5 are distinct from those necessary for SMAD2/3 phosphorylation. H1299 cells were co-transfected with wild-type ALK5, the T202D mutant which had previously been shown to constitutively activate TGFβ signaling, the K232R mutant which had been previously shown to inhibit TGFβ signaling and an ALK5-GFP fusion. At 24 hours post transfection protein was harvested and analyzed by western blot. Comparison of the P-p63 and P-SMAD2/3 signals indicated that T202D was unable to phosphorylate DNp63α but was able to phosphorylate SMAD2/3 (Lane 3). Remarkably the K232R mutant was able to phosphorylate DNp63α but not SMAD2/3 (Lane 4). These results suggest that the molecular mechanisms by which ALK5 phosphorylates DNp63α are distinct from those that phosphorylate SMAD2/3.

(PDF)

**Figure S3** Effects of three TGFβR2-directed siRNAs on expression of TGFβR2 and SMAD2 phosphorylation. H1299 cells were transfected with the indicated siRNAs and TGFβR2 and phospho-SMAD2 were analyzed to confirm the efficacy of the siRNA. SiRNA-C was used in the experiment shown in Figure 2C.

(PDF)

**Figure S4** Schematic representation of signal transduction pathways known to be downstream of the TGFβ receptor complex. Kinases associated with these pathways are shown in pink and the phospho-p63 vs total p63 IF score is shown as is the relationship of that score to the mean.

(PDF)

**Figure S5** Transfection of H1299 cells with ALK5-directed siRNA ablates immunofluorescent detection of ALK5. This data confirms the specificity of ALK5 detection presented in Figure 4E. This data confirms the selectivity of the ALK5 antibody.

(PDF)

**Figure S6** Representative Aldelfluor data from which Figure 5D was derived. Negative controls using the ALDH1 inhibitor DEAB are used to establish the gate separating ALDH<sup>High</sup> from ALDH<sup>High</sup> fractions.

(PDF)

**Figure S7** The anti-clonogenic effects of TGFβ are phenocopied by ectopic ALK5IKD. A. The anti-clonogenic effects of TGFβ on IMECs are partially rescued by the phospho-ablative DNp63α-AA mutant. Colony forming assay shown is representative of multiple experiments and corresponds to the graphical data displayed in Figure 7A. B. Ectopic expression of ALK5IKD is anti-clonogenic in IMEC cells. IMECs were transfected with pcDNA3.1-GFP and pcDNA3.1-ALK5IKD and selected in 200 μg/ml G418 for 12 days. Colonies were fixed in alcohol and stained with crystal violet. Graph at right represents a quantification of the colony formation in which colonies from three random 1 cm × 1 cm squares were analyzed using ImageJ software. Bars represent the average of three counts and error bars represent the standard error of the mean.

(PDF)

Acknowledgments

The authors wish to thank Dr. Lalage Wakefield for valuable advice and expertise in TGFβ signaling.

Author Contributions

Conceived and designed the experiments: JDR PC. Performed the experiments: SLJ JYL AJD. Analyzed the data: ALB JAH. Wrote the paper: JDR PC.

References